UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

	SEC FILE NUMBER
_	000-54402
	CUSIP NUMBER
_	090655408
Check one): [X] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-CEN [] Form N-CSR	
For Period Ended: December 31, 2019 [] Transition Report on Form 10-K [] Transition Report on Form 20-F [] Transition Report on Form 11-K [] Transition Report on Form 10-Q For the Transition Period Ended:	
Read Instruction (on back) Before Preparing Form. Please Print or Type.	
othing in this form shall be construed to imply that the Commission has verified any information contained herein.	
f the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:	

PART I - REGISTRANT INFORMATION

BIORESTORATIVE THERAPIES, INC.

Full Name of Registrant

Former Name if Applicable

40 Marcus Drive

Address of Principal Executive Office (Street and Number)

Melville, New York 11747

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X] []	(a) (b)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; The subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
[]	(c)	The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

As previously reported on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2020, on such date, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of New York (the "Bankruptcy Filing").

During the period leading up to and since the Bankruptcy Filing, the Company has been principally engaged in addressing bankruptcy-related matters. The Company's financial, accounting and administrative personnel and consultants have devoted substantially all of their time to the maintenance of the Company's ongoing operations, including the development of the Company's post-petition strategy and negotiations with regard to the potential sale of its assets.

pany will not be able to timely	-		

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification:			
	Mark Weinreb	(631)	760-8100	
	(Name)	(Area Coo	Code) (Telephone Number)	
(2)	1 1 1		es Exchange Act of 1934 or Section 30 of the Investment Company Act of 19 required to file such report(s) been filed? If answer is no, identify report(s)	
(3)	Is it anticipated that any significant change statements to be included in the subject report		orresponding period for the last fiscal year will be reflected by the earning No See below.	ngs
	If so, attach an explanation of the anticipated results cannot be made.	d change, both narratively and quantitat	itatively, and, if appropriate, state the reasons why a reasonable estimate of	the
Explanation of	of Anticipated Change			
Reference is	made to PART III – NARRATIVE			

BIORESTORATIVE THERAPIES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 31, 2020 By: /s/ Mark Weinreb

Mark Weinreb Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

- 1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
- One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.
- 3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
- 4. Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
- 5. Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).